Published in Sci Transl Med on June 05, 2013
Immunopathology of multiple sclerosis. Nat Rev Immunol (2015) 1.48
The spleen in local and systemic regulation of immunity. Immunity (2013) 1.33
A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano (2014) 1.16
The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Handb Clin Neurol (2014) 1.11
Overcoming immunological barriers in regenerative medicine. Nat Biotechnol (2014) 1.02
Nanoparticle delivery of donor antigens for transplant tolerance in allogeneic islet transplantation. Biomaterials (2014) 0.94
Food allergy: Insights into etiology, prevention, and treatment provided by murine models. J Allergy Clin Immunol (2014) 0.93
T cells in the control of organ-specific autoimmunity. J Clin Invest (2015) 0.93
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics (2016) 0.91
Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases. Crit Rev Immunol (2013) 0.90
Exploiting apoptosis for therapeutic tolerance induction. J Immunol (2013) 0.89
Harnessing nanoparticles for immune modulation. Trends Immunol (2015) 0.88
Toward beta cell replacement for diabetes. EMBO J (2015) 0.86
Biodegradable antigen-associated PLG nanoparticles tolerize Th2-mediated allergic airway inflammation pre- and postsensitization. Proc Natl Acad Sci U S A (2016) 0.85
Targeting Treg signaling for the treatment of autoimmune diseases. Curr Opin Immunol (2015) 0.85
Immunology: A tolerant approach. Nature (2014) 0.85
The role of dendritic cells in tissue-specific autoimmunity. J Immunol Res (2014) 0.84
Progression of relapsing-remitting demyelinating disease does not require increased TCR affinity or epitope spread. J Immunol (2014) 0.84
Tolerance strategies employing antigen-coupled apoptotic cells and carboxylated PLG nanoparticles for the treatment of type 1 diabetes. Rev Diabet Stud (2012) 0.83
Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng (2016) 0.83
Co-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis. AAPS J (2014) 0.83
Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities. Genome Biol (2016) 0.82
Preemptive donor apoptotic cell infusions induce IFN-γ-producing myeloid-derived suppressor cells for cardiac allograft protection. J Immunol (2014) 0.82
Cutting Edge: Nonobese Diabetic Mice Deficient in Chromogranin A Are Protected from Autoimmune Diabetes. J Immunol (2015) 0.81
Controlled release strategies for modulating immune responses to promote tissue regeneration. J Control Release (2015) 0.81
Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics (2016) 0.81
Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells. J Neuroimmunol (2014) 0.80
Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci Adv (2015) 0.80
Primary prevention of beta-cell autoimmunity and type 1 diabetes - The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) perspectives. Mol Metab (2016) 0.80
Lung transplantation: chronic allograft dysfunction and establishing immune tolerance. Hum Immunol (2014) 0.79
Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Sci Rep (2015) 0.78
Preemptive Tolerogenic Delivery of Donor Antigens for Permanent Allogeneic Islet Graft Protection. Cell Transplant (2014) 0.78
MS in South Asians in England: early disease onset and novel pattern of myelin autoimmunity. BMC Neurol (2015) 0.78
Manipulating regulatory T cells: a promising strategy to treat autoimmunity. Immunotherapy (2015) 0.78
Apoptotic cell responses in the splenic marginal zone: a paradigm for immunologic reactions to apoptotic antigens with implications for autoimmunity. Immunol Rev (2016) 0.78
Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease. Proc Natl Acad Sci U S A (2017) 0.78
An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy. Nanomedicine (2016) 0.78
Controlled Delivery of Single or Multiple Antigens in Tolerogenic Nanoparticles Using Peptide-Polymer Bioconjugates. Mol Ther (2017) 0.77
Mechanisms of immunological tolerance in central nervous system inflammatory demyelination. Clin Exp Neuroimmunol (2015) 0.77
Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis. Discov Med (2013) 0.77
Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol (2015) 0.77
Metabolic syndrome - Removing roadblocks to therapy: Antigenic immunotherapies. Mol Metab (2014) 0.76
A molecular view of multiple sclerosis and experimental autoimmune encephalitis: what can we learn from the epitope data? J Neuroimmunol (2013) 0.76
Concise Review: Cell-Based Therapies and Other Non-Traditional Approaches for Type 1 Diabetes. Stem Cells (2016) 0.76
Differential role of B cells and IL-17 versus IFN-γ during early and late rejection of pig islet xenografts in mice. Transplantation (2016) 0.75
Inducing immune tolerance: a focus on Type 1 diabetes mellitus. Diabetes Manag (Lond) (2013) 0.75
Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy. EBioMedicine (2016) 0.75
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis. J Transl Med (2016) 0.75
Future Therapies for IgE-Mediated Food Allergy. Curr Pediatr Rep (2014) 0.75
Administration of Myelin Basic Protein Peptides Encapsulated in Mannosylated Liposomes Normalizes Level of Serum TNF-α and IL-2 and Chemoattractants CCL2 and CCL4 in Multiple Sclerosis Patients. Mediators Inflamm (2016) 0.75
Tempering allorecognition to induce transplant tolerance with chemically modified apoptotic donor cells. Am J Transplant (2015) 0.75
Combination of an Antigen-Specific Therapy and an Immunomodulatory Treatment to Simultaneous Block Recurrent Autoimmunity and Alloreactivity in Non-Obese Diabetic Mice. PLoS One (2015) 0.75
Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm (2016) 0.75
Inducing tolerance one antigen at a time. Nat Biotechnol (2016) 0.75
Setting the target for pemphigus vulgaris therapy. JCI Insight (2017) 0.75
Biomimetic and synthetic interfaces to tune immune responses. Biointerphases (2015) 0.75
Infusion of Sulfosuccinimidyl-4-[N-maleimidomethyl]cyclohexane-1-carboxylate-Conjugated MOG35-55-Coupled Spleen Cells Effectively Prevents and Reverses Experimental Autoimmune Encephalomyelitis in Mice. J Immunol Res (2015) 0.75
CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line Disease-Modifying Therapies: A First-in-Human, Proof-of-Concept Dose-Escalation Study. Neurotherapeutics (2016) 0.75
Polyplexes assembled from self-peptides and regulatory nucleic acids blunt toll-like receptor signaling to combat autoimmunity. Biomaterials (2016) 0.75
IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis. J Immunol (2016) 0.75
Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8(+) T cell responses in type 1 diabetes. Diabetologia (2017) 0.75
A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146. Front Immunol (2017) 0.75
Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 40.64
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med (1987) 5.48
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature (1990) 4.40
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain (2001) 3.51
Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med (2006) 2.68
Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med (1995) 2.62
The induction of cell-mediated immunity and tolerance with protein antigens coupled to syngeneic lymphoid cells. J Exp Med (1979) 2.09
Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol (1990) 2.07
Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat Rev Immunol (2007) 2.00
Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann Neurol (2010) 1.89
Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. Nat Med (1996) 1.78
Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J Immunol (2000) 1.76
The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. J Immunol (1976) 1.68
ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A (2008) 1.63
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol (2011) 1.56
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci U S A (2004) 1.49
Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain (2000) 1.47
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol (2008) 1.43
Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.36
Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. J Immunol (1990) 1.34
A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology (1984) 1.24
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest (1997) 1.21
Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities. J Autoimmun (2006) 1.13
Antigen-fixed leukocytes tolerize Th2 responses in mouse models of allergy. J Immunol (2011) 1.13
Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. II. Fine specificity of effector T cell inhibition. J Immunol (1992) 1.08
Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest (1997) 1.07
Regulation of the effector stages of experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance induction. J Immunol (1990) 1.04
Anergy in vivo: down-regulation of antigen-specific CD4+ Th1 but not Th2 cytokine responses. Int Immunol (1994) 1.03
Successful treatment of paralytic relapses in adoptive experimental autoimmune encephalomyelitis via neuroantigen-specific tolerance. J Immunol (1991) 0.92
Antigen-specific therapies in MS - Current concepts and novel approaches. J Neurol Sci (2008) 0.88
Suppression of experimental autoimmune thyroiditis in guinea pigs by pretreatment with thyroglobulin-coupled spleen cells. Cell Immunol (1980) 0.87
Induction of peripheral tolerance with peptide-specific anergy in experimental autoimmune neuritis. Cell Immunol (1993) 0.87
Regression and spreading of self-recognition during the development of autoimmune demyelinating disease. J Autoimmun (1999) 0.85
Treatment of chronic relapsing experimental allergic encephalomyelitis with the intravenous administration of splenocytes coupled to encephalitogenic peptide 91-103 of myelin basic protein. J Neuroimmunol (1991) 0.80
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Immunology of multiple sclerosis. Annu Rev Immunol (2005) 9.08
Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol (2004) 5.15
Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J Immunol (2002) 4.95
Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol (2007) 4.87
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Averting biodiversity collapse in tropical forest protected areas. Nature (2012) 4.46
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med (2005) 4.43
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 4.26
Cutting Edge: Anti-CD25 monoclonal antibody injection results in the functional inactivation, not depletion, of CD4+CD25+ T regulatory cells. J Immunol (2006) 4.26
TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol (2003) 4.17
CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol (2007) 3.77
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 3.63
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation (2012) 3.12
Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat Biotechnol (2012) 3.11
Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol (2010) 2.99
Inhibitors of gamma-secretase block in vivo and in vitro T helper type 1 polarization by preventing Notch upregulation of Tbx21. Nat Immunol (2005) 2.81
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation. Pediatr Res (2004) 2.38
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A (2004) 2.37
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol (2009) 2.16
Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol (2009) 2.06
Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med (2014) 2.02
Differential activation of astrocytes by innate and adaptive immune stimuli. Glia (2005) 1.99
Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci (2002) 1.99
Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J (2005) 1.98
Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity (2010) 1.98
Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biol Blood Marrow Transplant (2005) 1.81
Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol (2013) 1.79
Development of biomarkers in multiple sclerosis. Brain (2004) 1.78
The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J Clin Invest (2007) 1.74
NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol (2010) 1.73
Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS One (2008) 1.72
Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain (2003) 1.71
The OSCAR-IB consensus criteria for retinal OCT quality assessment. PLoS One (2012) 1.67
[Criteria for evidence-based patient information]. Z Arztl Fortbild Qualitatssich (2005) 1.64
ECDI-fixed allogeneic splenocytes induce donor-specific tolerance for long-term survival of islet transplants via two distinct mechanisms. Proc Natl Acad Sci U S A (2008) 1.63
Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. Hum Mol Genet (2003) 1.59
De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J Immunol (2002) 1.58
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J Immunol (2004) 1.56
Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol (2011) 1.56
Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry (2011) 1.53
Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain (2006) 1.53
Cutting edge: ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis. J Immunol (2004) 1.52
A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest (2004) 1.51
Degenerate TCR recognition and dual DR2 restriction of autoreactive T cells: implications for the initiation of the autoimmune response in multiple sclerosis. Eur J Immunol (2008) 1.51
Cutting edge: central nervous system plasmacytoid dendritic cells regulate the severity of relapsing experimental autoimmune encephalomyelitis. J Immunol (2008) 1.47
Clinical nurse specialists and the practice of community nurses. J Adv Nurs (2006) 1.42
Participation preferences of patients with acute and chronic conditions. Health Expect (2007) 1.40
Glial toll-like receptor signaling in central nervous system infection and autoimmunity. Brain Behav Immun (2007) 1.40
Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol (2003) 1.39
The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta (2010) 1.38
Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J Immunol (2005) 1.38
Peripheral tolerance induction using ethylenecarbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis. J Immunol (2007) 1.36
The giant extracellular matrix-binding protein of Staphylococcus epidermidis mediates biofilm accumulation and attachment to fibronectin. Mol Microbiol (2009) 1.36
Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2005) 1.34
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med (2008) 1.33
Short DNA sequences inserted for gene targeting can accidentally interfere with off-target gene expression. FASEB J (2010) 1.33
Focal stimulation of the posterior parietal cortex increases the excitability of the ipsilateral motor cortex. J Neurosci (2007) 1.31
Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Mult Scler (2013) 1.30
JC virus granule cell neuronopathy and GCN-IRIS under natalizumab treatment. Ann Neurol (2013) 1.29
Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci (2004) 1.28
Innate and adaptive immune responses of the central nervous system. Crit Rev Immunol (2006) 1.28
Role of ICAM-1 and P-selectin expression in the development and effector function of CD4+CD25+regulatory T cells. J Autoimmun (2003) 1.28
Local temperatures inferred from plant communities suggest strong spatial buffering of climate warming across Northern Europe. Glob Chang Biol (2013) 1.28
Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res (2013) 1.27
PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur J Immunol (2008) 1.27
Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest (2003) 1.26
Retinal damage in multiple sclerosis disease subtypes measured by high-resolution optical coherence tomography. Mult Scler Int (2012) 1.24
A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain (2010) 1.24
The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance. Eur J Immunol (2002) 1.24
Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler (2012) 1.23
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler (2013) 1.22
Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain (2011) 1.22
Distinct roles of protein kinase R and toll-like receptor 3 in the activation of astrocytes by viral stimuli. Glia (2007) 1.21
Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain (2010) 1.21
T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol (2012) 1.21
Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler (2003) 1.19
Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol Rev (2009) 1.19
Structure of a TCR with high affinity for self-antigen reveals basis for escape from negative selection. EMBO J (2011) 1.17
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol (2011) 1.17
Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol (2009) 1.16